

Michael R Freeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11811263/publications.pdf>

Version: 2024-02-01

83
papers

8,289
citations

57681

46
h-index

75989

78
g-index

86
all docs

86
docs citations

86
times ranked

11209
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. <i>Clinical Cancer Research</i> , 2022, 28, 414-424.	3.2	14
2	Antioxidant functions of DHHC3 suppress anti-cancer drug activities. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2341-2353.	2.4	12
3	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 5850.	1.7	2
4	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1689784.	5.5	57
5	Comprehensive palmitoyl-proteomic analysis identifies distinct protein signatures for large and small cancer-derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1764192.	5.5	37
6	27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 671-684.	1.5	35
7	Low-Background Acyl-Biotinyl Exchange Largely Eliminates the Coisolation of Non-S-Acylated Proteins and Enables Deep S-Acylproteomic Analysis. <i>Analytical Chemistry</i> , 2019, 91, 9858-9866.	3.2	32
8	Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. <i>Clinical Proteomics</i> , 2019, 16, 15.	1.1	15
9	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 252-259.	2.0	71
10	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.4	49
11	Personalization of prostate cancer therapy through phosphoproteomics. <i>Nature Reviews Urology</i> , 2018, 15, 483-497.	1.9	25
12	Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1505403.	5.5	286
13	CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 1662-1673.	0.4	83
14	Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. <i>Prostate</i> , 2017, 77, 446-457.	1.2	20
15	High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients. <i>RNA Biology</i> , 2017, 14, 305-316.	1.5	43
16	The current evidence on statin use and prostate cancer prevention: are we there yet?. <i>Nature Reviews Urology</i> , 2017, 14, 107-119.	1.9	111
17	Universal Solid-Phase Reversible Sample-Prep for Concurrent Proteome and N-Glycome Characterization. <i>Journal of Proteome Research</i> , 2016, 15, 891-899.	1.8	5
18	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. <i>Oncotarget</i> , 2015, 6, 11327-11341.	0.8	289

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicles in Cancer: Exosomes, Microvesicles and the Emerging Role of Large Oncosomes. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 41-51.	2.3	675
20	Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. <i>Scientific Reports</i> , 2015, 5, 12136.	1.6	48
21	Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. <i>BMC Urology</i> , 2015, 15, 80.	0.6	12
22	Technologies and Challenges in Proteomic Analysis of Protein S-acylation. <i>Journal of Proteomics and Bioinformatics</i> , 2014, 07, 256-263.	0.4	18
23	Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 409-418.	1.5	64
24	Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. <i>Proteomics</i> , 2014, 14, 1845-1856.	1.3	44
25	Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells. <i>Cell Communication and Signaling</i> , 2014, 12, 44.	2.7	24
26	Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 530.	0.8	12
27	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. <i>Journal of Pathology</i> , 2013, 231, 77-87.	2.1	93
28	Statin Drugs and Prostate Cancer: Time to Consider Proactive Strategies in Patients. <i>Journal of Urology</i> , 2013, 189, 1192-1193.	0.2	1
29	Large oncosomes mediate intercellular transfer of functional microRNA. <i>Cell Cycle</i> , 2013, 12, 3526-3536.	1.3	189
30	The Role of Cholesterol in Prostate Cancer. , 2013, , 65-83.		0
31	Caveolin-1 and Prostate Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2012, 729, 95-110.	0.8	33
32	Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. <i>American Journal of Pathology</i> , 2012, 181, 1573-1584.	1.9	321
33	Cholesterol and prostate cancer. <i>Current Opinion in Pharmacology</i> , 2012, 12, 751-759.	1.7	218
34	Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. <i>PLoS ONE</i> , 2012, 7, e30062.	1.1	108
35	DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. <i>EMBO Molecular Medicine</i> , 2012, 4, 743-760.	3.3	92
36	The Response of the Prostate to Circulating Cholesterol: Activating Transcription Factor 3 (ATF3) as a Prominent Node in a Cholesterol-Sensing Network. <i>PLoS ONE</i> , 2012, 7, e39448.	1.1	9

#	ARTICLE	IF	CITATIONS
37	The Complex Interplay Between Cholesterol and Prostate Malignancy. <i>Urologic Clinics of North America</i> , 2011, 38, 243-259.	0.8	61
38	Cholesterol and benign prostate disease. <i>Differentiation</i> , 2011, 82, 244-252.	1.0	43
39	Proteomic analysis of palmitoylated platelet proteins. <i>Blood</i> , 2011, 118, e62-e73.	0.6	105
40	An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2011, 47, 2-9.	0.7	40
41	A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death. <i>Cancer Biology and Therapy</i> , 2011, 12, 966-977.	1.5	23
42	Quantitative Proteomics Identifies a β -Catenin Network as an Element of the Signaling Response to Frizzled-8 Protein-Related Antiproliferative Factor. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.007492.	2.5	31
43	Proteome Scale Characterization of Human S-Acylated Proteins in Lipid Raft-enriched and Non-raft Membranes. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 54-70.	2.5	252
44	Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer. <i>Journal of Proteome Research</i> , 2010, 9, 3073-3082.	1.8	26
45	Suppression of aberrant transient receptor potential cation channel, subfamily V, member 6 expression in hyperproliferative colonic crypts by dietary calcium. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G593-G601.	1.6	31
46	Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease. <i>Cancer Research</i> , 2009, 69, 5601-5609.	0.4	325
47	Heterogeneous Nuclear Ribonucleoprotein K Is a Novel Regulator of Androgen Receptor Translation. <i>Cancer Research</i> , 2009, 69, 2210-2218.	0.4	51
48	An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation. <i>Cell Cycle</i> , 2009, 8, 2420-2424.	1.3	141
49	Ezetimibe Is an Inhibitor of Tumor Angiogenesis. <i>American Journal of Pathology</i> , 2009, 174, 1017-1026.	1.9	100
50	Proteomic approaches to the analysis of multiprotein signaling complexes. <i>Proteomics</i> , 2008, 8, 832-851.	1.3	45
51	Do the cholesterol-lowering properties of statins affect cancer risk?. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 113-121.	3.1	109
52	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. <i>Cell Cycle</i> , 2008, 7, 2257-2267.	1.3	80
53	Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update. <i>Tumori</i> , 2008, 94, 633-639.	0.6	60
54	Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. <i>Cancer Biology and Therapy</i> , 2007, 6, 1269-1274.	1.5	47

#	ARTICLE	IF	CITATIONS
55	Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in Membrane Raft Microdomains. <i>Journal of Biological Chemistry</i> , 2007, 282, 29584-29593.	1.6	78
56	Cholesterol Sensitivity of Endogenous and Myristoylated Akt. <i>Cancer Research</i> , 2007, 67, 6238-6246.	0.4	114
57	Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. <i>Steroids</i> , 2007, 72, 210-217.	0.8	55
58	The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. <i>EMBO Journal</i> , 2007, 26, 4523-4534.	3.5	116
59	Cholesterol, Cell Signaling, and Prostate Cancer. , 2007, , 119-137.		1
60	The role of cholesterol in prostate cancer. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006, 9, 379-385.	1.3	124
61	Marked Disturbance of Calcium Homeostasis in Mice With Targeted Disruption of the Trpv6 Calcium Channel Gene. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 274-285.	3.1	251
62	A quantitative proteomic analysis of growth factor-induced compositional changes in lipid rafts of human smooth muscle cells. <i>Proteomics</i> , 2005, 5, 4733-4742.	1.3	60
63	Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 273-279.	3.1	88
64	Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. <i>Journal of Clinical Investigation</i> , 2005, 115, 959-968.	3.9	264
65	Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. <i>Journal of Clinical Investigation</i> , 2005, 115, 959-968.	3.9	454
66	Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells. <i>Endocrinology</i> , 2004, 145, 613-619.	1.4	70
67	HER2/HER3 heterodimers in prostate cancer. <i>Cancer Cell</i> , 2004, 6, 427-428.	7.7	24
68	Cholesterol and prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 54-69.	1.2	237
69	Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function. <i>Endocrinology</i> , 2002, 143, 4599-4608.	1.4	55
70	Calcium-Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and Is Aberrantly Expressed in Human Malignancies. <i>Laboratory Investigation</i> , 2002, 82, 1755-1764.	1.7	222
71	Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. <i>Cancer Research</i> , 2002, 62, 2227-31.	0.4	249
72	CaT1 Expression Correlates with Tumor Grade in Prostate Cancer. <i>Biochemical and Biophysical Research Communications</i> , 2001, 282, 729-734.	1.0	165

#	ARTICLE	IF	CITATIONS
73	Vascular Endothelial Growth Factor-Mediated Autocrine Stimulation of Prostate Tumor Cells Coincides with Progression to a Malignant Phenotype. <i>American Journal of Pathology</i> , 2001, 159, 651-659.	1.9	90
74	A novel method for implantation of LNCaP prostate tumor cells under the renal capsule. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2001, 37, 360-362.	0.7	3
75	AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 1999, 277, C294-C301.	2.1	87
76	Angiogenic switch and vascular stability in human Leydig cell tumours. <i>Angiogenesis</i> , 1999, 3, 231-240.	3.7	9
77	Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. <i>Urology</i> , 1999, 54, 523-527.	0.5	245
78	Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. , 1998, 68, 328-338.		38
79	Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. , 1998, 69, 143-153.		103
80	Temperature-controlled laser photocoagulation of soft tissue: In vivo evaluation using a tissue welding model. <i>Lasers in Surgery and Medicine</i> , 1996, 18, 335-344.	1.1	78
81	Human albumin solder supplemented with TGF- β 1 accelerates healing following laser welded wound closure. <i>Lasers in Surgery and Medicine</i> , 1996, 19, 360-368.	1.1	60
82	Human albumin solder supplemented with TGF- β 1 accelerates healing following laser welded wound closure. , 1996, 19, 360.		2
83	Phenotypic and Cytogenetic Characterization of Human Bladder Urothelia Expanded in Vitro. <i>Journal of Urology</i> , 1994, 152, 665-670.	0.2	230